Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel cationic liposome hepatic arterial infusion plus systemic therapy for first-line advanced colorectal cancer with liver metastases
CTR20251628Phase 3Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of paclitaxel cationic liposome in colorectal cancer (CRC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jun 2025; status: active.
02
Drugs
paclitaxel cationic liposome
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20251628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251628.